Prof. Byoung Chul Cho, MD, PhD
Yonsei Cancer Center
Yonsei University College of Medicine J
JE-UK Laboratory of Molecular Cancer Therapeutics
Seoul, Korea
In South Korea, how are you using NGS-based molecular profiling in the setting of NSCLC? (Korean)
In South Korea, how are you using NGS-based molecular profiling in the setting of NSCLC?
How do the capabilities of NGS compare to hot spot testing, and why is whole exome sequencing based on hot spot panels preferred in the setting of precision oncology practice?
In what spectrum of tumors and at what point in the natural history of the disease do you use NGS-based molecular profiling?
What is the value of molecular profiling in the first line setting? (Korean)
What is the value of molecular profiling in the first line setting?
Since genomic alterations change as a cancer evolves, how do we employ whole exome genomic profiling as part of a longitudinal patient management strategy?
Why is hybrid capture-based sequencing the optimal molecular profiling platform in the context of precision cancer medicine? And can you use long cancer as an example of how NGS can generate specific drug alignments?